Modification(s)

None

Gene ID number

7040

Cross reactivity

Human

Swiss Prot

P01137

Subcellular location

Secreted

French translation

anticorps

Target Antigen

TGF beta 1

Immunogen range

100-150/390

Concentration

1ug per 1ul

Conjugation

Unconjugated

Also known as

TGF beta 1 PAb

Category

Primary Antibodies

Modification site(s)

Unmodified antibody

Clonality

Polyclonal antibody

Clone number

Polyclonal antibody

Tested Applications

WB, IHC-P, IF(IHC-P)

Long name

TGF beta 1 Primary Polyclonal Antibody

Purification method

This antibody was purified via Protein A.

Recommended dilutions

WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)

Specificity

This is a highly specific antibody against TGF beta 1.

Synonym names

CED; LAP; DPD1; TGFB; TGFbeta; Transforming growth factor beta-1; TGF-beta-1; TGFB1

Cross reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human TGF beta 1/LAP

Storage conditions

Keep the antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for up to 1 year.

Properties

If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the target antigen

Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells.